Evidence map›Paper›PMID 40280970›Full record

ArticleNPJ vaccines2025

Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors.

Shiv K Sethi, Claire E Bradley, Lukas Bialkowski, Yuk Ying Pang, Cynthia D Thompson, John T Schiller, Nicolas Çuburu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shiv K SethiNational Cancer Institute, NIH, Bethesda, MD, USA.
Claire E Bradley *National Cancer Institute, NIH, Bethesda, MD, USA.
Lukas Bialkowski *National Cancer Institute, NIH, Bethesda, MD, USA.
Yuk Ying PangNational Cancer Institute, NIH, Bethesda, MD, USA.
Cynthia D ThompsonNational Cancer Institute, NIH, Bethesda, MD, USA.
John T SchillerNational Cancer Institute, NIH, Bethesda, MD, USA.
Nicolas ÇuburuNational Cancer Institute, NIH, Bethesda, MD, USA. cuburun@mail.nih.gov.

Funding

Intramural Research Program NIH
6 · The paper itself

Abstract

Intratumoral (IT) immunotherapy can stimulate the tumor microenvironment and enhance anti-tumor immunity. We investigated IT delivery of three licensed viral vaccines-Shingrix (VZV shingles), Gardasil-9 (HPV), and Spikevax (SARS-CoV-2)-in prevaccinated mice using the murine tumor model TC-1, which expresses HPV16 oncogenes E6 and E7. Shingrix IT injection often induced tumor regression and resistance to secondary challenge. Injecting a VZV glycoprotein E (gE)-derived MHC-II-restricted peptide with polyI:C also led to durable remission, highlighting the role of gE-specific CD4

Identifiers

PMID40280970
PMCPMC12032097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.